APPLICATION
ANDA078789
TYPE
ANDA
ORIGINAL APPROVAL
2011-06-01
LATEST ACTION
2024-05-31
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued
Products
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEDiscontinued
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2024-05-31Labeling · Supplement 12 · standardAP
2023-06-06Labeling · Supplement 10 · standardAP
2023-06-06Labeling · Supplement 7 · standardAP
2023-06-06Labeling · Supplement 11 · standardAP
2023-06-06Labeling · Supplement 8 · standardAP
2015-10-02Labeling · Supplement 6 · standardAP
2014-01-29Labeling · Supplement 4 · standardAP
2014-01-29Labeling · Supplement 2 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.